1.69
price down icon3.43%   -0.06
after-market アフターアワーズ: 1.75 0.06 +3.55%
loading
前日終値:
$1.75
開ける:
$1.73
24時間の取引高:
1.03M
Relative Volume:
0.75
時価総額:
$162.64M
収益:
-
当期純損益:
$-217.44M
株価収益率:
-0.7788
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
+36.29%
1か月 パフォーマンス:
-13.33%
6か月 パフォーマンス:
-58.06%
1年 パフォーマンス:
-60.70%
1日の値動き範囲:
Value
$1.62
$1.79
1週間の範囲:
Value
$1.20
$1.86
52週間の値動き範囲:
Value
$1.115
$8.27

Prime Medicine Inc Stock (PRME) Company Profile

Name
名前
Prime Medicine Inc
Name
セクター
Healthcare (1176)
Name
電話
617-465-0013
Name
住所
60 FIRST ST., CAMBRIDGE
Name
職員
214
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
PRME's Discussions on Twitter

PRME を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PRME
Prime Medicine Inc
1.69 162.64M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.89B 3.81B -644.79M -669.77M -6.24

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 開始されました JMP Securities Mkt Outperform
2024-05-20 開始されました H.C. Wainwright Buy
2024-05-16 アップグレード Citigroup Neutral → Buy
2024-04-22 開始されました Chardan Capital Markets Buy
2024-04-08 開始されました TD Cowen Buy
2024-04-03 開始されました Wedbush Outperform
2024-01-16 ダウングレード Stifel Buy → Hold
2023-12-08 開始されました Citigroup Neutral
2023-10-09 開始されました BMO Capital Markets Outperform
2023-07-31 開始されました Guggenheim Buy
2023-04-18 開始されました Stifel Buy
2022-11-14 開始されました Goldman Neutral
2022-11-14 開始されました JP Morgan Overweight
2022-11-14 開始されました Jefferies Buy
2022-11-14 開始されました Morgan Stanley Equal-Weight
すべてを表示

Prime Medicine Inc (PRME) 最新ニュース

pulisher
10:51 AM

Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359 - Seeking Alpha

10:51 AM
pulisher
Apr 24, 2025

Top investors say Prime Medicine Inc (PRME) ticks everything they need - Sete News

Apr 24, 2025
pulisher
Apr 23, 2025

Prime Medicine Inc (PRME) gets rating Initiated from JMP Securities - knoxdaily.com

Apr 23, 2025
pulisher
Apr 21, 2025

Breaking down PRME’s current quarter earnings estimates - uspostnews.com

Apr 21, 2025
pulisher
Apr 19, 2025

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $13.38 - Defense World

Apr 19, 2025
pulisher
Apr 15, 2025

11,426 Shares in Prime Medicine, Inc. (NYSE:PRME) Acquired by American Century Companies Inc. - Defense World

Apr 15, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics - Benzinga

Apr 11, 2025
pulisher
Apr 01, 2025

There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News

Apr 01, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Mar 30, 2025
pulisher
Mar 26, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Wedbush Estimates Prime Medicine FY2029 Earnings - The AM Reporter

Mar 23, 2025
pulisher
Mar 22, 2025

Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Why Prime Medicine Stock Was Climbing Higher This Week - AOL.com

Mar 21, 2025
pulisher
Mar 20, 2025

Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 19, 2025

Why Prime Medicine Stock Is Soaring Today - Yahoo

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks

Mar 19, 2025
pulisher
Mar 18, 2025

Prime Medicine advances AATD gene editing therapy - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine unveils program for treatment of AATD - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Launches Preclinical Program for Liver Treatments -March 18, 2025 at 07:34 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy Rating - TipRanks

Mar 18, 2025
pulisher
Mar 15, 2025

Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga

Mar 15, 2025
pulisher
Mar 14, 2025

Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com

Mar 12, 2025
pulisher
Mar 10, 2025

Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex

Mar 10, 2025
pulisher
Mar 10, 2025

Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World

Mar 07, 2025
pulisher
Mar 04, 2025

Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks

Mar 04, 2025

Prime Medicine Inc (PRME) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
大文字化:     |  ボリューム (24 時間):